Australia's most trusted
source of pharma news
Saturday, 10 May 2025
Posted 8 May 2025 PM
The pharmaceutical industry is gearing up to take a far more aggressive public posture in lobbying against the Donald Trump-backed policy of 'most favoured nation' drug pricing.
Pharmas have announced tens of billions of dollars of investment in US pharmaceutical manufacturing in recent months in an attempt to mollify Trump and convince him not to put tariffs on pharmaceutical products and inputs.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.